BLLN (BillionToOne) Tax Expense: $0.7 Mil (TTM As of Mar. 2026)


BLLN BillionToOne Inc BLLN
13 GF Score
Price $122.33
! 5 Warning Signs
View Full Analysis

What is BillionToOne Tax Expense?

BillionToOne BLLN +2.04% 13 Tax Expense is $0.7 Mil as of Mar. 2026. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

BillionToOne's tax expense for the months ended in Mar. 2026 was $0.5 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.7 Mil.


BillionToOne  (NAS:BLLN) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


BillionToOne Tax Expense Related Terms


BillionToOne Tax Expense Historical Data

* Premium members only.

The historical data trend for BillionToOne's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BillionToOne Tax Expense Chart

BillionToOne Annual Data
Trend Dec23 Dec24 Dec25
Tax Expense
0.01 0.03 0.31

BillionToOne Quarterly Data
Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Expense Get a 7-Day Free Trial 0.10 0.01 -0.13 0.32 0.54
BLLN
13GF Score
BillionToOne Inc BLLN
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BillionToOne Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of $0.7 Mil mean?
BillionToOne (BLLN) has a Tax Expense of $0.7 Mil as of Mar. 2026. Tax expense is the amount of tax the company pays in an accounting period. View historical data on BillionToOne and its competitors.
Is BillionToOne's Tax Expense too high?
BillionToOne's current Tax Expense is $0.7 Mil. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Tax Expense compare to SHC and VCYT?
BillionToOne's Tax Expense of $0.7 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Medical Diagnostics & Research company?
A good Tax Expense depends on the Medical Diagnostics & Research industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on BillionToOne and its competitors. BillionToOne's current Tax Expense is $0.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Tax Expense of $0.7 Mil. The current Tax Expense is $0.7 Mil. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For BillionToOne (BLLN), the current Tax Expense is $0.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BillionToOne Business Description

Address 1035 O’Brien Drive, Menlo Park, CA, USA, 94025
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score

Get the complete analysis for BLLN

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$122.33
Price